Major Growth Driver: Increasing focus on human microbiome therapeutics development

Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). Microbes are rich sources of enzymes, owing to which they can be used in various therapeutic applications, such as the search for novel therapies.

In the last decade, microbiome therapy has gained widespread importance. During a 10-year timespan (fiscal years 2007–2016), the National Institutes of Health (NIH) invested USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP over fiscal years 2012–2016. Similarly, the European Commission established Metagenomics of the Human Intestinal Tract project (MetaHIT), which is mainly focused on gut bacteria.

From 2008 to 2012, ~USD 15 million was invested in this project. From 2012 to 2018 ~USD 14 million (EUR 12 million) was invested in MetaCardis (Metagenomics in Cardiometabolic Diseases), which is a major EU-funded research project that investigated the role of gut microbes in cardiometabolic diseases (CMDs). Similarly, Horizon 2020 is one of the biggest EU Research and Innovation programs with funding of nearly USD 96.9 million (€80 billion) available over seven years (2014 to 2020).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Opportunity: Increasing collaborations between public-private organizations

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

Recent Developments:

# In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.

# In 2020, BiomX collaborated with Boehringer Ingelheim to utilize the microbiome-based biomarker discovery platform to potentially identify biomarkers associated with patient phenotypes in Inflammatory Bowel Disease (IBD).

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

Report Objectives:

# To define, describe, segment, and forecast the human microbiome market based on product, application, disease, and region

# To define, describe, segment, and forecast the human microbiome research spending market based on technology

# To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)

# To strategically analyze micromarkets and subsegments with respect to individual growth trends, future prospects, and contributions to the overall human microbiome market

# To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

# To forecast the size of market segments concerning four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (South America, Latin America, and the Middle East & Africa)

# To strategically analyze the market structure and profile the key players of the global human microbiome market and comprehensively analyze their core competencies

# To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; and product launches in the human microbiome market

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Expected Revenue Growth:

The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.

The Asia Pacific region is the fastest growing region of human microbiome research spending market in 2019

On the basis of region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2019.

In 2019, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2020-2025. Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.

Global Key Players:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).

Various growth strategies have been adopted by these players, such as agreements, collaborations, partnerships, and acquisitions to increase their presence in the global human microbiome market.

Read More Detailed Report@
https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]